53MEDIUM

LDX

LUMOS FPO [LDX]
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.
Healthcare · ASX Small Cap
$0.2650 +0.0%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical61
Catalyst32
Sentiment50
Fundamental54
Momentum79
Risk Gate45
Get alerts when LDX's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track LDX — Free

Active Signals

Bullish Signals

  • Beating the Small Ords index — relative strength of 1.16, so it's outpacing the pack
  • Trading above the 200-day average — the long-term trend is on your side
  • Adequate cash runway (5 quarters)
  • EPS estimates revised downward (-10pts)
  • CANSLIM I: Institutional ownership (19%)
  • Turned profitable (NPAT positive from results)
  • Sentiment is mixed — no strong consensus either way
  • Strong long-term momentum — up 811% over the past year (excluding last month)
  • Excellent risk-adjusted returns — Sharpe of 2.1 means strong gains without wild swings
  • The bigger volume days are the up days — volume-weighted momentum is positive (0.55%/day)
  • Beneish M-Score -1.98 (grey zone -2.22 to -1.78): possible earnings manipulation
  • RBA hiking (-3pts)

Risk Signals

  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-76%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about LDX
"What's driving LDX's score?" "How does LDX compare to peers?" "Key risks for LDX?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NEGATIVE Trading Halt
NONE Section 708A Cleansing Statement
NONE Application for quotation of securities - LDX
NONE Lumos Delivers Several Pivotal Milestones in 1H FY26
LOW 1H FY26 Results Investor Presentation

Recent ASX Announcements

2026-03-24 Trading Halt PRICE SENSITIVE
2026-03-04 Section 708A Cleansing Statement
2026-03-04 Application for quotation of securities - LDX
2026-03-02 1H FY26 Results Investor Presentation
2026-02-26 Lumos Delivers Several Pivotal Milestones in 1H FY26 PRICE SENSITIVE

Key Metrics

$211.4M
Market Cap
2.9M
Avg Volume
0.9x
Vol Ratio
$0.02 — $0.33
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-123.3%
ROE
-75.8%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 51%
LLeader vs LaggardlaggardRS: -2
IInstitutional SponsorshippassInst: 19%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #14 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:LDX vs ATXLDX vs PNVLDX vs IMM
Scout Pro — Deeper Analysis for LDX
Try Pro free for 30 days
Share this analysis

Track LDX and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required